Topiramate use early in pregnancy and the risk of oral clefts

Objective To assess the relative risk of oral clefts associated with maternal use of high and low doses of topiramate during the first trimester for epilepsy and nonepilepsy indications. Methods This population-based study nested in the US 2000–2010 Medicaid Analytic eXtract included a cohort of 1,360,101 pregnant women with a live-born infant enrolled in Medicaid from 3 months before conception through 1 month after delivery. Oral clefts were defined as the presence of a recorded diagnosis in claims during the first 90 days after birth. Women with a topiramate dispensing during the first trimester were compared with those without any dispensing and with an active reference group of women with a lamotrigine dispensing during the first trimester. Risk ratios (RRs) were estimated with generalized linear models with fine stratification on the propensity score of treatment to control for potential confounders. Stratified analyses by indication of use and dose were conducted. Results The risk of oral clefts at birth was 4.1 per 1,000 in the 2,425 infants born to women exposed to topiramate compared with 1.1 per 1,000 in the unexposed group (RR 2.90, 95% confidence interval [CI] 1.56–5.40). The RR among women with epilepsy was 8.30 (95% CI 2.65–26.07); among women with other indications such as bipolar disorder, it was 1.45 (95% CI 0.54–3.86). The median daily dose for the first prescription filled during the first trimester was 200 mg for women with epilepsy and 100 mg for women without epilepsy. For topiramate monotherapy, the RR for oral clefts associated with doses ≤100 mg was 1.64 (95% CI 0.53–5.07) and for doses >100 mg it was 5.16 (95% CI 1.94–13.73). Results were similar when lamotrigine was used as a reference group. Conclusion The increased risk of oral clefts associated with use of topiramate early in pregnancy was more pronounced in women with epilepsy, who used higher doses.

[1]  K. Rothman,et al.  Topiramate use in pregnancy and the birth prevalence of oral clefts , 2014, Pharmacoepidemiology and drug safety.

[2]  W. Hauser,et al.  Association Between Topiramate and Zonisamide Use During Pregnancy and Low Birth Weight , 2014, Obstetrics and gynecology.

[3]  W. Callaghan,et al.  Development of a Comorbidity Index for Use in Obstetric Patients , 2013, Obstetrics and gynecology.

[4]  Mary K. Kowal,et al.  Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations , 2013, PloS one.

[5]  M. Gissler,et al.  Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. , 2013, JAMA.

[6]  S. Hernández-Díaz,et al.  Algorithms to estimate the beginning of pregnancy in administrative databases , 2013, Pharmacoepidemiology and drug safety.

[7]  S. Hernández-Díaz,et al.  Use of topiramate in pregnancy and risk of oral clefts. , 2012, American journal of obstetrics and gynecology.

[8]  Mark W. Green,et al.  Utilization of Topiramate During Pregnancy and Risk of Birth Defects , 2012, Headache.

[9]  W. Hauser,et al.  Comparative safety of antiepileptic drugs during pregnancy , 2012, Neurology.

[10]  A. Powell.  Two-year sustained weight loss and metabolic benefits with controlled-release Phentermine/Topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2012 .

[11]  P. G. Larsson,et al.  Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population , 2011, Epilepsy Research.

[12]  A. Hviid,et al.  Newer-generation antiepileptic drugs and the risk of major birth defects. , 2011, JAMA.

[13]  R. Kirby,et al.  Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. , 2010, Birth defects research. Part A, Clinical and molecular teratology.

[14]  H. Bays.  Phentermine, topiramate and their combination for the treatment of adiposopathy (‘sick fat’) and metabolic disease , 2010, Expert review of cardiovascular therapy.

[15]  M. Martinez-frias,et al.  TOPIRAMATE IN PREGNANCY: PRELIMINARY EXPERIENCE FROM THE UK EPILEPSY AND PREGNANCY REGISTER , 2009, Neurology.

[16]  L. Holmes,et al.  Valproate teratogenicity and epilepsy syndrome , 2008, Epilepsia.

[17]  S. Hernández-Díaz,et al.  Positive predictive value of computerized records for major congenital malformations , 2008, Pharmacoepidemiology and drug safety.

[18]  M. Eadie,et al.  The Australian Register of Antiepileptic Drugs in Pregnancy: The first 1002 pregnancies , 2007, The Australian & New Zealand journal of obstetrics & gynaecology.

[19]  M. Cunnington,et al.  Effect of Dose on the Frequency of Major Birth Defects Following Fetal Exposure to Lamotrigine Monotherapy in an International Observational Study , 2007, Epilepsia.

[20]  L. Finer,et al.  Perspectives on sexual and reproductive health , 2002 .

[21]  B. Irwin,et al.  Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[22]  M. Dam,et al.  Epilepsy and pregnancy: lamotrigine as main drug used , 2004, Acta neurologica Scandinavica.

[23]  T. Einarson,et al.  Malformation Rates in Children of Women with Untreated Epilepsy , 2004, Drug safety.

[24]  M Maclure,et al.  Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. , 2001, American journal of epidemiology.

[25]  R. Finnell,et al.  Anticonvulsant Drugs: Mechanisms and Pathogenesis of Teratogenicity , 1997 .

[26]  O. Heinonen,et al.  Risk factors for ventricular septal defect in Finland. , 1991, Public health.

[27]  R. Finnell,et al.  Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades; 2: Human studies. , 1991, Reproductive toxicology.

[28]  M. Friis,et al.  Facial clefts in sibs and children of epileptic patients , 1986, Neurology.

[29]  S. Shapiro,et al.  ANTICONVULSANTS AND PARENTAL EPILEPSY IN THE DEVELOPMENT OF BIRTH DEFECTS , 1976, The Lancet.